Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Feb 04, 2024 3:12pm
357 Views
Post# 35862024

RE:RE:RE:Roche

RE:RE:RE:RocheNot sure why you consider the phase 3 Roche trial information as deceptive?
The phase 2 trail was set up with Roche as the " Gobblet" blanket of 4 cohorts.
Three of which were showed efficacy results @ very early indication.
Good news for Panc. As most don't live very long.
Moving forward to a phase 3 trial as that combo- therapy makes 100% sense.
What that relationship is called  & or funding has yet to be announced.
Recall was or set up as a precision promise modified phase 3 under the control of PanCan.
With thst cancelled, the question then becomes how to fund this trial?
Will Roche be a comercial/ financial partener? Will Roch share the trial costs?
Will Roche supply product & watch from outside?
The slide deck does not answer any of those questions.
what we know for sure, the Roche cotherapy will be the basis of the phase 3.
Respectfully, anything posted on a corporate web site is vetted by lawyers.
using riches name? They would need permission from Roche. And that answe would be vetted through Roche lawyers.
corporate publications are not like this chat site. Your accusation of being deceptive is very naive to the business world as a whole.
if you look at the end of the slide deck there are 6-7 corporate logos.
They are all protected under copyright. Meaning to use them, requires corporate consent.
none of which would be given without much due diligence.
The last thing any company would want is to have their good name/ product/ etc dragged into anything close to deceptive, etc etc.
Again, please stop the silly Ad hominem attacks. Roche is well aware of what Onc has posted.
Ambiguous? Vauge ?
Without an announcement business deal, that's the best either side can say.
We can only hope Roche steps up & buys the whole thing.

<< Previous
Bullboard Posts
Next >>